PFE Stock Recent News

When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector.

When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector.

Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump administration's promised tariffs were set to go into effect the following day, and the sector has been mentioned as a key area of focus for these.

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. The current market uncertainty has sparked investor interest in exchange-traded funds and there are plenty to choose from. Since no two funds are equal, you need to choose one based on your goals, risk, and investment horizon. Schwab has several funds that attract investor interest but one fund stands apart for dividend income investors. If you do not want to risk investing in individual stocks but want to enjoy steady passive income, consider Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD). Key points in this article: The ongoing market uncertainty has drawn investors towards low-risk ETFs. The Schwab U.S. Dividend equity ETF has shown steady dividend growth for 12 years. If you think you aren’t anywhere close to your retirement goals, check out the SmartAsset’s free tool that can match you with a financial advisor in minutes to help yo

March winds bring April showers.

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease, the company said on Tuesday.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company's bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now.

Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.

Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.